DNLI 주가 차트
DNLI 수입
Denali Therapeutics Inc
$18.92
1.33%
$0.25
종가: May 05, 16:00:00 GMT-4
$19.03
0.58%
$0.1
애프터마켓: May 05, 20:00:00 GMT-4
뒤로
Denali Therapeutics Inc (DNLI) 수입
최신 수익 결과: Q4 '25
보고됨: 2026-02-26
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
DNLI의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Denali Therapeutics Inc DNLI의 지난 분기 매출 실적은 어땠나요?
Denali Therapeutics Inc의 매출 추정치는 얼마인가요?
Denali Therapeutics Inc의 수익 품질 점수는 얼마인가요?
Denali Therapeutics Inc는 언제 수익을 보고하나요?
Denali Therapeutics Inc의 예상 수익은 얼마인가요?
Denali Therapeutics Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$18.67
시가
$19.15
일일 범위
$18.33 - $19.4
52주 범위
$12.31 - $23.77
거래량
2.2M
평균 거래량
1.7M
배당수익률
--
EPS(TTM)
-2.97
시가총액
$3.0B
DNLI란 무엇인가요?
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. The company is headquartered in South San Francisco, California and currently employs 503 full-time employees. The company went IPO on 2017-12-08. The firm is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. The company has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). The company is also exploring programs in oncology, inflammation, and other diseases.
